What Granite Bio does

Granite Bio AG is a clinical-stage immunology company headquartered in Basel, Switzerland, developing first-in-class therapeutic antibodies for inflammatory, autoimmune, and fibrotic conditions. The company's pipeline is built around two lead candidates: GRT-001, a monoclonal antibody that selectively depletes pro-inflammatory monocytes via ADCC/ADCP mechanisms (an approach the company characterizes as "Innate Rituximab"), which completed a Phase 1a study in healthy volunteers with positive safety and pharmacological activity and is currently in Phase 1b testing in patients with inflammatory bowel disease; and GRT-002, a first-in-class antibody that blocks interleukin-3 (IL-3) to address autoimmune inflammation and type II inflammation including itch and allergy, currently in preclinical development with clinical entry expected in 2026.

Both programs originated from research conducted by Professor Matthias Mack at the University of Regensburg and were advanced through Versant's Ridgeline Discovery Engine in Basel. The company is privately held and venture-backed, having raised $100 million in April 2025 across a $30 million Series A led by Versant Ventures and Novartis Venture Fund and a $70 million Series B led by Forbion and Sanofi Ventures. In October 2025, Granite Bio entered into an option-to-acquire agreement with Novartis covering its immuno-inflammatory programs.

Granite Bio is pre-revenue and does not yet commercialize any products. Its go-to-market approach contemplates standard pharmaceutical commercialization through specialty distribution channels following regulatory approval. Near-term economic value is most directly tied to clinical milestones and to the Novartis option agreement, which functions as both a development partnership and a potential exit vehicle. The senior team — drawn from Roche, Novartis, GSK, AstraZeneca, Bristol Myers Squibb, Novo Nordisk, and prior successful biotech ventures — is structured to execute clinical-stage development across discovery, translational medicine, clinical operations, clinical pharmacology, and CMC.

Name

Granite Bio

Legal name

Granite Bio AG

Website

https://granitebio.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

11–50 employees

Short description

Granite Bio is a clinical-stage immunology company in Basel, Switzerland, developing first-in-class therapeutic antibodies for inflammatory, autoimmune, and fibrotic diseases, with lead asset GRT-001 in Phase 1b testing for inflammatory bowel disease.

Ownership category

akta.pro rank

Product category

Therapeutic Antibodies

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

Keywords

• Therapeutic antibodies
• Inflammatory disease treatment
• Autoimmune therapy development
• Fibrotic disorder treatment
• Biopharmaceutical drug development

Headquarters

HQ city

Basel

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Therapeutic antibody commercialization: Pre-revenue clinical-stage biotechnology company. Revenue will be generated through commercialization of therapeutic antibody candidates (GRT-001 and GRT-002) upon successful regulatory approval for treatment of inflammatory, autoimmune and fibrotic conditions.

Go-to-market motion1 record

Marketing channels3 records

Core offering

Granite Bio develops two first-in-class therapeutic antibodies for inflammatory, autoimmune, and fibrotic disorders. GRT-001 depletes pro-inflammatory monocytes via an ADCC/ADCP mechanism ("Innate Rituximab") and is in Phase 1b testing for inflammatory bowel disease. GRT-002 blocks interleukin-3 to address autoimmune and type II inflammation (itch and allergy) and is in preclinical development with clinical trials expected in 2026.

Product overview

Granite Bio is a clinical-stage biotechnology company developing two first-in-class therapeutic antibodies targeting inflammatory, autoimmune, and fibrotic conditions. The pipeline consists of GRT-001 (depletes pro-inflammatory monocytes via ADCC/ADCP, currently in Phase 1b for IBD) and GRT-002 (blocks interleukin-3 for autoimmune/type II inflammation, in preclinical development). Both antibody programs were developed in collaboration with Versant's Ridgeline Discovery Engine in Basel, Switzerland.

Differentiator

Problem solved

Functional benefit

Products and services

• GRT-001 First-in-class antibody that depletes pro-inflammatory monocytes via an ADCC/ADCP mechanism, described as an "Innate Rituximab." Completed Phase 1a in healthy volunteers showing a positive safety profile and clear pharmacological activity; currently in Phase 1b testing in patients with inflammatory bowel disease. Developed for treatment of inflammatory and autoimmune conditions.
• GRT-002 First-in-class antibody that blocks interleukin-3 (IL-3), a key player in autoimmune inflammation and type II inflammation. Targets a novel disease biology node identified through proprietary patient profiling. In preclinical development, with expected entry into clinical trials in 2026 for treatment of itch and allergy.

Quantifiable outcome

• GRT-001 completed Phase 1a in healthy volunteers showing positive safety profile and clear pharmacological activity
• +1 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core.

• NovartiscoreStrategic or Co-development Partner · 28 October 2025Option-to-purchase agreement to advance development of potential first-in-class therapies for immuno-inflammatory diseases. Collaboration leverages Novartis's deep expertise and global development capabilities to advance Granite Bio's programs toward patients in need.
• Versant Ridgeline Discovery EnginecoreTechnology or Integration · 24 April 2025Both lead antibody molecules were developed in collaboration with Versant's Ridgeline Discovery Engine in Basel, Switzerland. The Ridgeline Discovery Engine provides infrastructure and capabilities for antibody discovery and development.
• University of Regensburg (Prof. Matthias Mack)coreStrategic or Co-development Partner · 24 April 2025Both lead antibody programs originated from the laboratories of Professor and Scientific Co-Founder Matthias Mack at University of Regensburg. This academic collaboration provides the foundational science for Granite Bio's therapeutic candidates.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• AnaptysBio: Clinical-stage biotechnology company developing antibody therapeutics for inflammatory and autoimmune diseases. Direct peer given overlapping therapeutic areas (IBD, immunology) and antibody-based modality, with comparable clinical-stage profile.
• MorphoSys: Was a leading clinical-stage antibody biotech focused on autoimmune and inflammatory diseases before its acquisition by Novartis in 2024. Direct historical peer in autoimmune antibody development and a relevant comp for Granite Bio's Novartis relationship.
• AbCellera Biologics: Clinical-stage antibody discovery and development company with autoimmune and inflammatory disease programs, including partnered assets in immunology. Comparable given antibody modality and immunology therapeutic focus.
• Pandion Therapeutics: Was a clinical-stage biotech developing antibody therapeutics for autoimmune diseases (acquired by Merck in 2021). Direct historical peer in autoimmune antibody modality with similar pre-clinical/early-clinical profile.

Emerging players

• Disc Medicine: Clinical-stage immunology and hematology biotech developing antibody-based therapeutics. Comparable given early clinical-stage immunology focus and antibody modality, though focused on hematology indications.
• Avalo Therapeutics: Clinical-stage immunology and inflammation biotech with pipeline assets in immune-mediated diseases. Comparable given clinical-stage immunology/inflammation focus, though using multiple modalities beyond antibodies.
• Arcutis Biotherapeutics: Dermatology and immunology-focused biotech with commercial-stage product (ZORYVE) and pipeline in inflammatory skin conditions. Comparable given clinical-stage inflammation focus, though commercial-stage rather than early clinical.

Broad incumbents

• AbbVie: Major pharmaceutical company with leading immunology franchise including Humira, Skyrizi, and Rinvoq for IBD and other autoimmune conditions. Relevant incumbent competitor with overlapping indications and established physician relationships.
• Eli Lilly: Major pharmaceutical company with significant immunology franchise (Taltz, Olumiant) and active biologics pipeline. Broad incumbent with overlapping therapeutic areas and antibody capabilities.
• Sanofi: Major pharmaceutical company with leading immunology franchise (Dupixent) and active autoimmune biologics pipeline. Broad incumbent in autoimmune/immunology space; also a Granite Bio investor via Sanofi Ventures.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/granitebio

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Granite Bio